UCB en­ters gene ther­a­py space, ink­ing li­cense agree­ment for epilep­sy and neu­rode­gen­er­a­tion re­search

UCB may not have any gene ther­a­py can­di­dates on the mar­ket or pub­licly in its pipeline, but that hasn’t stopped the phar­ma from ink­ing a mul­ti-year li­cense agree­ment with Clear­Point Neu­ro to work on drug de­liv­ery plat­forms for UCB’s gene ther­a­py port­fo­lio, ac­cord­ing to the com­pa­nies.

As part of the agree­ment, UCB will use Clear­Point Neu­ro’s tech and ser­vices to de­vel­op and com­mer­cial­ize UCB’s gene ther­a­py prod­ucts and Clear­Point will re­ceive suc­cess-based mile­stone pay­ments. More fi­nan­cial de­tails of the agree­ment weren’t de­scribed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER